Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Quality of Life Data From Clinical Trials in RCC

April 13th 2022

Dr Ornstein weighs in on interpreting quality of life data from important RCC trials to help with treatment decision-making.

Is There a Role for Biomarkers in Advanced RCC?

April 13th 2022

Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with RCC.

Adjuvant and Neoadjuvant Therapies Under Evaluation for Renal Cell Carcinoma

April 8th 2022

Expert perspectives on the possible roles of neoadjuvant nivolumab and adjuvant sunitinib for patients with renal cell carcinoma.

Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab

April 8th 2022

A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.

Treatment Strategies for Patients With RCC and Brain or Bone Metastases

April 6th 2022

Drs Barata and Ornstein describe how they treat certain subgroups of patients with advanced RCC, particularly those with brain or bone metastases.

Choosing The Appropriate Frontline Therapy in Advanced RCC: IO-TKI vs IO-IO Therapies

April 6th 2022

7.Dr Ornstein explains how he selects between IO-TKI and IO-IO therapy in the first-line setting in advanced RCC.

First-Line IO-TKI Combination Treatment Regimens for Advanced RCC

April 5th 2022

A review of the first-line IO/TKI combination regimens available for advanced RCC and the factors considered in choosing an appropriate treatment.

Patient Profile Presentation: A 58-Year-Old Woman Presenting with Gross Hematuria

April 5th 2022

Arnab Basu, MD, presents the patient profile of a 58-year-old woman with advanced renal cell carcinoma presenting with gross hematuria.

Dr. Vaishampayan on the PROBE Trial in Advanced RCC

April 5th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.

Advanced Renal Cell Carcinoma: Clinical Practice Pearls

April 4th 2022

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Lenvatinib/Pembrolizumab in RCC: Dosing and Adverse Event Management

April 1st 2022

Expert perspectives on lenvatinib/pembrolizumab combination therapy in renal cell carcinoma, including appropriate dosing and adverse event management.

Risk Stratification and Factors in Selecting Therapy in RCC

April 1st 2022

Shared insight on the patient and disease factors that inform the selection of therapy for favorable-risk renal cell carcinoma.

What Factors Should be Taken Into Consideration When Choosing The Fist-Line Therapy in RCC?

March 30th 2022

Dr Bilen discusses factors to consider when choosing a first-line therapy for advanced clear-cell RCC

First-Line Therapy of Advanced RCC With Nivolumab + Ipilimumab: CheckMate 214 Study

March 30th 2022

David Braun, MD, delves into data from the CheckMate 214 trial that focused on ipilimumab with nivolumab.

Role of Community and Academic Centers in the Treatment of Patients with Advanced RCC

March 28th 2022

Dr Sumeet Bhatia highlights the challenges faced by community oncologists who treat patients with advanced renal cell carcinoma and which patients they refer to academic centers.

Toxicities and Quality of Life with IO-IO Therapies in Patients with Advanced RCC

March 28th 2022

Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.

Patient Profile 2: Favorable-Risk RCC Treated With Lenvatinib-Pembrolizumab

March 25th 2022

A second clinical scenario focusing on favorable-risk renal cell carcinoma managed with lenvatinib-pembrolizumab therapy.

Triplet Therapy Approaches for Intermediate/Poor Risk RCC

March 25th 2022

A brief discussion on triplet therapy being investigated in patients with intermediate- and poor-risk renal cell carcinoma.

First-Line Therapy of Advanced RCC With Cabozantinib + Nivolumab: CheckMate 9ER Study

March 23rd 2022

Moshe C. Ornstein, MD, MA, explains the results from the CheckMate 9ER trial that studied cabozantinib with nivolumab.

First-Line Therapy of Advanced RCC With Axitinib + Pembrolizumab: KEYNOTE-426 Study

March 23rd 2022

Pedro C. Barata, MD, MSc, reviews the data from the KEYNOTE-426 trial, which focused on axitinib with pembrolizumab.